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Background: People with neuromuscular disorders (NMD) exhibit weak coughs and are susceptible to recurrent
chest infections and acute respiratory complications, the most frequent reasons for their unplanned hospital
admissions. Mechanical insufflation-exsufflation (MI-E) devices are a non-invasive method of increasing peak cough
flow, improving cough efficacy, the clearance of secretion and overcoming atelectasis. There is limited published
evidence on the impact of home use MI-E devices on health service utilisation. The aims of the study were: to
assess the self-reported health and lifestyle benefits experienced as a result of home use of MI-E devices; and evaluate
the effects of in-home use of MI-E devices on Emergency Department (ED) presentations, hospital admissions
and inpatient length of stay (LOS).
Methods: Individuals with NMD who were accessing a home MI-E device provided through Muscular Dystrophy
Western Australia were invited to participate in a quantitative survey to obtain information on their experiences
and self-assessed changes in respiratory health. An ad-hoc record linkage was performed to extract hospital, ED
and mortality data from the Western Australian Department of Health (DOHWA). The main outcome measures
were ED presentations, hospital separations and LOS, before and after commencement of home use of an MI-E
device.
Results: Thirty seven individuals with NMD using a MI-E device at home consented to participate in this study.
The majority (73%) of participants reported using the MI-E device daily or weekly at home without medical assistance
and 32% had used the machine to resolve a choking episode. The survey highlighted benefits to respiratory function
maintenance and the ability to manage increased health care needs at home. Not using a home MI-E device was
associated with an increased risk of ED presentations (RR = 1.76, 95% CI 1.1-2.84). The number of hospital separations
and LOS reduced after the use of MI-E device, but not significantly. No deaths were observed in participants using the
MI-E device at home.
Conclusions: Home use of a MI-E device by people living with NMD may have a potential impact on reducing their
health service utilisation and risk of death. Future research with greater subject numbers and longer follow-up periods
is recommended to enhance this field of study.
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Neuromuscular disorders (NMD) are a heterogeneous
group of inherited or acquired diseases characterized by
progressive muscle weakness and wasting which may
affect either one or all of the major respiratory muscle
groups (inspiratory, expiratory, and bulbar). Thus, re-
spiratory deterioration is often the primary cause of both
morbidity and mortality in people with NMD. As muscle
weakness and wasting progress NMD patients lose the
ability to cough effectively and clear respiratory secre-
tions. This can lead to aspiration of salivary and oral
contents, atelectasis, frequent recurrent respiratory in-
fections, pneumonias and airway obstruction [1-4].
Respiratory complications in NMD had once been
considered inevitable [5]. Advances in the management
and treatment over the last 30 years have dramatically
improved the overall morbidity and mortality in NMD
[6,7]. Traditionally, the management of airway clearance
involved intensive physiotherapy in combination with a
ventilator and manually assisted coughing [8,9]. How-
ever, repeated intensive physiotherapy treatment is both
labor-intensive and tiring for the patient. Mechanical
insufflation-exsufflation (MI-E) devices, such as the
CoughAssist™ device (Respironics INC, Murraysville, PA,
USA) are a non-invasive alternative which have gained
widespread acceptance in recent years [9]. MI-E devices
simulate a natural cough by using positive airway pres-
sure to insufflate the lung (via a face mask), followed by
a rapid shift to negative pressure and lung exsufflation.
Techniques to promote cough and enhance mucociliary
clearance have been mainstay treatments of NMD patients
during episodes of acute respiratory deterioration and are
now being used proactively [6-8,10,11]. Multiple studies
have demonstrated the clinical benefit of MI-E in patients
living with NMD [6-8,10,12]. In adults with NMD, MI-E
results in significantly increased peak cough flow [13-17],
decreased treatment time [18], improved oxygen satur-
ation and decreased dyspnoea [16], and the potential to
decrease mechanical ventilation time [19]. In children,
MI-E has been shown to significantly increase peak
cough flow [18] and is well tolerated and safe [20,21].
Further studies comparing the use of MI-E in combin-
ation with other therapeutic interventions describe
the need to monitor respiratory status when making
respiratory management decisions [22].
Limited studies have examined the impact of home
use of MI-E devices on health service utilisation. Moran
et al., conducted a retrospective chart review of seven
children with NMD using a MI-E device at home and
found a significant reduction in inpatient length of stay
at six and twelve months following commencement of
home use of a MI-E device. The qualitative parental survey
highlighted positive benefits of using a MI-E device, in par-
ticular the ability to treat many pulmonary exacerbationsat home [9]. Guidelines for respiratory management from
the British Thoracic Society, developed from a body of
evidence including case studies, recommends homecare
treatment includes the use of manually-assisted cough
techniques such as the MI-E device and is associated with
decreased hospital admission for respiratory infection [23].
The current study included both children and adults
with a sample size of 37, and had follow up periods up
to five years to evaluate the effects of in-home use of a
MI-E device, on ED presentations, pulmonary related
hospital separations and inpatient length of stay; and
assess the self-reported health and lifestyle benefits ex-




As part of an outreach and support service program,
Muscular Dystrophy Western Australia (MDWA) pro-
vided 45 NMD patients access to a MI-E device
(CoughAssist™) at home between December 2007 and
November 2011. An allied health professional provided
instruction to patients and/or their families and carers
on using the MI-E device. Patients then used the MI-E
device at home throughout the study period and were
able to seek assistance for using the device from
MDWA or other health services when required.
Each study participant, or their parent/guardian for
participants under the age of 18 years, completed a self-
administered paper based questionnaire. The survey in-
strument allowed for the collection of qualitative data
regarding the use of the MI-E device, the self-assessed
effects on participant’s respiratory function and satisfac-
tion with the device. The survey instrument can be
found in Additional file 1.
Health record linkage
An ad-hoc linkage between participants and three
DOHWA administrative datasets was performed by the
Data Linkage Unit, DOHWA using the probabilistic
linkage method [24]. Participants’ hospital inpatient and
emergency department records were extracted from the
Hospital Morbidity Data System (HMDS) between
1988–2012 and the Emergency Department Data Collec-
tion (EDDC) between 2005–2012. The death dataset of the
Registry of Birth, Deaths and Marriages was used to deter-
mine whether any participants died during the study
period.
An intervention study design was used to compare
health service use pre and post commencing home use
of the MI-E device. Respiratory related International
Classification of Diseases (ICD), Tenth Revision, Australian
Modification (ICD-10-AM) and ICD Ninth Revision,
Clinical Modifications (ICD-9-CM) codes were used for
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ist and a medical coding specialist. The codes are listed
in Additional file 1.
Statistical analysis
All three outcome measures (dependent variables) were
modelled using a negative binomial regression (to allow
for overdispersion) with a log link function fitted in SAS
version 9.3 (SAS Institute, Cary, NC, USA). LOS was
calculated as time from admission to separation minus
leave days. The explanatory variables in the model were
time period, sex and access to a MI-E device at home
(the intervention). Time period was used as a surrogate
variable for disease progression.
For the HMDS data extracted for the 25 years between
1988–2012, the variable for time period was constructed
in the form of 25 one year intervals relative to the inter-
vention date (the date at which an individual received
their MI-E device) such that there were up to a total of
20 intervals before intervention and up to five intervals
after intervention. For ED data, extracted for the eight
years between 2005–2012, the variable for time period
was constructed in the form of eight one year intervals
relative to the intervention date, totalling up to three in-
tervals before intervention and up to five intervals after
intervention. Our analysis took into account the amount
of time clinical data was available for each person. For
every one year period, the total number of person days
contributed for the year by each person was calculated.
As participants began using the MI-E device at different
times, person days contributed were not equal for all pe-
riods for all cohort members. Logarithmic person daysTable 1 Demographic characteristics of study participants an











Administration of MI-E device Self-ad
With s
MI-E device has ever been used to resolve a choking episode Yes
Nowere modelled as an offset term that is equivalent to
modelling the dependent variable as a rate model [25].
This study was approved by the Human Research Ethics
Committee of the DOHWA.
Results
Patient survey
Thirty seven of the 45 patients who were invited to partici-
pate in this study consented to take part in the study; a par-
ticipation rate of 82%. Table 1 shows the demographic
characteristics and results from the survey. The majority of
participants (73%) were male, the mean age of participants
at time of receiving the machine was 19.8 years (range 1–
59 years). The participants used the MI-E devices for 0.1 -
4.0 years, with a mean duration of 2.3 years (median
2.5 years). More than 80% of participants resided in the
metropolitan area. Of 37 cases, more than half (55.6%) had
a diagnosis of muscular dystrophy (MD), of which included
approximately three quarters of the male participants. The
remaining participant’s (male and female) had a variety of
NMD diagnoses including spinal muscular atrophy (SMA),
limb girdle MD, congential myopathies, arthrogryposis
multiplex congenital and congenital MD.
The majority of participants (92%) reported that the
MI-E device was being administered with support either
from a family member or a support worker. The majority
of participants used the device either daily (46%) or weekly
(27%). One third reported they had used the MI-E device
to resolve a choking episode. Thirty three (88%) partici-
pants either strongly agreed or agreed that home MI-E
had improved their/their child’s overall respiratory health.















upport from family member and/or support worker 34 (91.9)
12 (32.4)
25 (67.6)
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ported that they would recommend the use of a home
MI-E device to other people living with NMD.
Analysis of qualitative responses indicates that partici-
pants perceived that use of a home MI-E device had led
to improvements of their/their child’s respiratory func-
tion, prevented respiratory infections and complications
and allowed the pro-active management of respiratory
events. The device’s ease of use, the ability to manage
health care needs at home and the reduction in hospita-
lisations were also reported as positive features. Finally,
participants reported that having access to a MI-E device
at home provided peace of mind that episodes of chok-
ing could be managed quickly and effectively, with some
participants describing the device as a “lifesaver”.
Only one-third of participants reported negative features
of using the MI-E device. The most commonly reported
negative features were the size and weight of the machine
and the time required to administer the device.
Health record linkage
Links to hospital morbidity data were found for all 37
study participants, however, only 23 (62%) study partici-
pants were admitted to hospital for a respiratory related
condition over the study period. Among those participants
who had been admitted to hospital for a respiratory re-
lated condition, the mean and median total number of
respiratory hospital separations between 1988–2012
was 3.1 and 2.0 respectively.
Links to ED data were found for 29 (78%) study par-
ticipants. The mean and median number of total ED
presentations amongst these study participants betweenFigure 1 Hospital separations, inpatient LOS and person time contributed2005–2012 were 7.1 and 6.0 presentations respectively.
No links to death data were found for any participant,
indicating that none of the participants in the study
cohort died during the study period.
Figure 1 illustrates the hospital separations, inpatient
LOS and person time contributed by time period for the
study cohort. The person time increases over the study
period as additional participants enter the cohort and re-
mains constant after intervention (time period 20).
While there is an overall increasing trend, although not
statistically significant, in both hospital separations and
inpatient LOS over the study period, there is consider-
able fluctuation from one time period to the next. The
person time for ED presentation also increased until
intervention (Figure 2). There was an overall decreasing
trend, although not statistically significant, in ED presen-
tations after intervention.
The relative risk (RR) of hospital separations, inpatient
LOS and ED presentation before and after intervention
were shown in Table 2. Males with NMD had lower risk
compared to females with NMD in all 3 outcomes. After
adjusting for gender, person years and time period, the risk
of hospitalisations (RR = 1.82, 95% CI = 0.76-4.38) and
LOS (RR = 2.83, 95% CI = 0.52-15.49) at pre-intervention
were higher than post-intervention, but this was not statis-
tically significant. The home use of an MI-E device was
shown to be significantly associated with reduced ED pre-
sentations (RR = 1.76, 95% CI =1.10-2.84).
Discussion
This study demonstrated that using MI-E devices at
home improves self-reported health and lifestyle factorsby time period.
Figure 2 Emergency department presentations and person time contributed by time period.
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ing respiratory infections; the ability to manage respira-
tory illness at home. Participants reported they would
recommend the program to other patients with NMD.
These survey findings are congruent with those reported
by Moran et al. [9].
Patients and their families/carers reported the device
provided reassurance and peace of mind that acute
choking episodes could be managed quickly and effect-
ively. This is particularly important considering choking
is a significant cause of death in NMD patients [14].
Patients had almost two and three times higher hospi-
talisations and LOS at pre-intervention, respectively, but
the results are not statistically significant. The non-
significant results may be explained by the fact that 27%
of participants did not use the device regularly (less than
weekly) and the limited time frame in which participants
were followed after receiving a MI-E device. The regularity
of home MI-E use among NMD patients may depend on
their changing health needs and disease progression.Table 2 Relative risk of hospital separations, inpatient LOS an
Hospital separation
RR (95% CI)
Gender Male 0.44 (0.24 - 0.8)
Female 1.0
Intervention Pre 1.82 (0.76 - 4.38)
Post 1.0
Time period 1.10 (1.04 -1.17)Advantages of frequent use include not only the mainten-
ance of health but familiarity with the device, resulting in
patients and their families/carers feeling more confident in
using the device during an acute respiratory episode, such
as choking [21,9]. Hence, regular access to this equipment
by the provision of continual home access programs may
be more effective than programs that provide only inter-
mittent access to MI-E devices.
The use of a MI-E device was significantly associated
with a reduction of NMD patients’ ED presentations. It
is not known whether all of the ED presentations both
pre and post intervention were respiratory related since
the ED data had missing values in the diagnosis field.
Nevertheless, the reduction in ED presentations is a desir-
able outcome for patients and the health system to reduce
patient's and family’s stress and overcrowding in emer-
gency departments [26,27].
The increasing trend over time in hospital separations
and inpatient LOS are most likely explained by two fac-
tors: 1) the gradual increase in the number of participantsd ED presentations
s Inpatient LOS ED presentations
RR (95% CI) RR (95% CI)
0.21 (0.07 - 0.63) 0.42 (0.31 - 0.58)
1.0 1.0
2.83 (0.52 - 15.49) 1.76 (1.10 - 2.84)
1.0 1.0
1.15 (1.01 – 1.27) 1.05 (0.95 – 1.16)
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progression among study participants that results in a
deterioration of respiratory function and an increase in
respiratory morbidity and therefore hospitalisation. Add-
itionally, the variation of participants age and disease sta-
tus may well have masked any underlying trend.
The limitations of this study are characteristic of the
common logistical and statistical challenges of studies
evaluating medical interventions for rare diseases mainly
attributed to small patient numbers [28]. The lack of
control group is a limiting but inevitable factor due to
the nature of the disease group and the small population
of people living with NMD in WA. This makes finding
suitable controls matched on age, sex and diagnosis im-
practicable. Due to the low subject numbers, it is not
possible to stratify subjects further on disease types, re-
gularity of MI-E device use, children and adults. There is
a gender imbalance which is also due to the low sample
size. The age range of patients in this study has resulted
in the variability in disease progression and limited the po-
tential to reach significance. For the analysis, time period
was used as a surrogate variable for disease progression,
however, this has limitations because of the individual
variability in disease progression.
Finally, information about self-reported respiratory
health and disease was not available prior to home use
of a MI-E device as the patient survey was a retrospective
study. This study was therefore limited to questioning
participants about their perspectives regarding changes
in their overall respiratory health since commencing
the use of a MI-E device.
Conclusion
This is the first report examining the impact of home
use of MI-E on hospital service use in a study popula-
tion of both adults and children with NMD. Study re-
sults found that in-home use of a MI-E device was
associated with a significant reduction in ED presenta-
tions and associated with a number of perceived health
and lifestyle benefits. Future research requires matched
controls to people with NMD who are not using a MI-E
device and longer follow-up periods after commence-
ment of home use of a MI-E device. Participants need
better education on the regular use of the machine to
maximise the benefit. In addition, the use of validated
quality of life tools as suggested by Moran et al. [9] or a
more in-depth, exploratory approach to qualitatively
examine the impact of home use of a MI-E device would
greatly enhance research to assist in planning of health
services and home assistance.
Considering the already complex care needs of people
living with NMD, it is important that medical technologies
introduced into patient homes do not result in an un-
acceptable increase in burden of care.Additional file
Additional file 1: Included are data of hospital separations,
inpatient LOS and ED presentations, respiratory-related codes and
the survey instrument. Data of hospital separations, inpatient LOS and
total time contributed by sex and time period (Table S1), and
intervention and time period (Table S2). Data of ED presentations and
total time contributed by sex and time period (Table S3), and
intervention and time period (Table S4). Table S5 lists the respiratory
related International Classification of Diseases (ICD), Tenth Revision,
Australian Modification (ICD-10-AM) and ICD Ninth Revision, Clinical
Modifications (ICD-9-CM) codes used for this analysis based on advice
from a respiratory specialist and a medical coding specialist. Table S6 is
the survey instrument used for the collection of qualitative data
regarding the use of the MI-E device, the self-assessed effects on
participant’s respiratory function and satisfaction with the device.
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